Earnings call transcript: VistaGen Therapeutics reports Q3 FY2025 net loss
VistaGen Therapeutics Inc . (NASDAQ:VTGN) reported a net loss of $14.1 million for the third quarter of fiscal year 2025, compared to a net loss of $6.4 million in the same period last year. The ...
Earnings call transcript: Applied DNA Sciences Q1 FY25 revenue grows
Applied DNA Sciences Inc (NASDAQ:APDN) reported its financial results for the first quarter of fiscal year 2025, showcasing a notable increase in revenue but also highlighting ongoing challenges with ...